• THE STATE OF AI
ENGLAND
About us...
“AI systems require large volumes of high- quality data to learn effectively but healthcare data often involves privacy concerns, is fragmented across different systems or is unavailable due to regulatory constraints.”
aspect of healthcare provision. Key concerns such as data privacy, algorithmic transparency, and ensuring the accuracy and reliability of AI-generated advice were central to these developments. The UK, Europe, and the USA are adopting multi-faceted approaches to tackle bias and transparency in generative AI tools. In Europe, the focus is on regulatory measures, with the European Union proposing the Artificial Intelligence Act, aimed at setting strict compliance requirements for AI systems to ensure fairness and transparency. This includes guidelines for high-risk AI applications, ensuring they are subject to rigorous testing and certification. The UK, while aligning with similar principles, is leveraging its National AI Strategy and the work of bodies like the Centre for Data Ethics and Innovation (CDEI) to address these challenges. This strategy includes developing ethical frameworks and enhancing public-private partnerships for responsible AI deployment. In the USA, efforts are concentrated on policy initiatives and regulatory oversight, with agencies like the FDA increasingly scrutinising AI-based medical devices for biases. The White House Office of Science and Technology Policy (OSTP) has also emphasised the importance of AI ethics and governance. Across all these regions, there is a common emphasis on advancing research in AI fairness, investing in diverse and inclusive data sets, and fostering collaboration between government, academia, and industry. This is complemented by initiatives to educate and train AI developers and users in ethical AI practices, aiming to integrate transparency and bias mitigation into the fabric of AI development and deployment. In conclusion, generative AI is gradually being introduced into the healthcare sector, and it is still in a nascent stage as a tool for providing healthcare advice. However, its widespread adoption is an inevitability and those companies and healthcare systems most able to adapt to its specific requirements and benefits will benefit greatly in terms of patient outcomes and healthcare costs.
• Bias and generalisability. AI models can perpetuate biases present in training data, leading to inequitable or inaccurate outcomes for certain patient groups. Collaborative development involving healthcare professionals, AI experts, and patients can enhance the relevance and usability of AI solutions. • Integrating AI into existing healthcare workflows poses logistical and technical challenges, requiring significant changes in the infrastructure and training of healthcare professionals. Addressing these challenges is critical for the successful and ethical implementation of AI in MedTech. Currently, there are no widespread implementations of generative AI specifically for providing healthcare advice in the UK and Europe. The field is rapidly evolving, however. Generative AI is being explored in the provision of healthcare advice in the UK and Europe, although its usage is subject to stringent regulatory oversight and ethical considerations. In the UK, for instance, the National Health Service (NHS) has been investigating the potential of AI, including generative models, to support clinical decision-making and patient management. This included pilot projects for AI-assisted diagnosis and personalised treatment recommendations. Similarly, in various European countries, there were initiatives to integrate AI into healthcare systems, focusing on enhancing diagnostic accuracy, patient engagement, and preventive care. However, these applications were usually in controlled environments, often for research or in a limited capacity, rather than being a standard
HecoAnalytics is committed to supporting healthtech and lifescience companies to gain the health analytics capability needed to robustly assess and sell their products to a global digital health economy. The company provides consulting services to life science companies including health economics, market access, pricing and reimbursement strategy, regulatory, business planning and technical due diligence. Increasingly the company’s focus is on Machine Learning, AI and digital health applications where it has particular technical expertise. To provide ongoing market access support to clients HecoAnalytics provides an easy-to-use health analytics platform supporting companies
on a personalised health economics (HE) journey. HecoAnalytics facilitation sessions start this journey and support companies with a suite of configurable tools that synthesise evidence data, AI pathway and patient models with online health economic models. HecoAnalytics tools are aligned with the requirements of the National Institute of Care and Health Excellence (NICE) technology assessment (HTA) programmes such as the Medical Technologies Evaluation Programme (MTEP), demonstrating the value of a company’s product to NICE and other HTA bodies and payers.
an efficient process, giving access to these resources rather than traditional labour-intensive paper-based reports. AI’s ability to process and analyse vast amounts of data can help identify the most efficient allocation of resources, predict patient outcomes, and evaluate the cost-benefit of various healthcare strategies. It can also assist in modelling the long-term economic impacts of healthcare decisions, considering disease progression, quality of life and potential healthcare savings. This will lead to more informed, data-driven decisions that balance patient needs with economic sustainability. The integration of AI in MedTech, while promising, faces several challenges: • Data quality and availability. AI systems require large volumes of high-quality data to learn effectively but healthcare data often involves privacy concerns, is fragmented • Interpretability. Many AI models, particularly deep learning systems, are often seen as “black boxes”, making it difficult for healthcare professionals to understand how these models function, which is crucial for clinical decision-making. This lack of transparency can also hinder trust and acceptance among medical practitioners. • Regulatory hurdles present a significant challenge. The healthcare industry is highly regulated, and obtaining approval for AI-based medical devices and across different systems or is unavailable due to regulatory constraints. tools is a complex and lengthy process. Additionally, ensuring that these systems are compliant with healthcare standards and regulations, like HIPAA in the U.S., is essential but challenging.
hecoanalytics.com
30 | irglobal
irglobal | 31
Made with FlippingBook flipbook maker